Global Women Healthcare Market Research Report- Forecast To 2023

Global Women Healthcare Market Research Report- Forecast To 2023

ID: MRFR/HC/2248-CRR | June, 2017 | Region: Global | 130 pages | Cooked Research Reports

Global Women Healthcare Market Information; by Indication (Postmenopausal Osteoporosis, Infertility, Reproductive Health Management, Polycystic Ovary Syndrome, Gynecologic Cancer and others) by diagnosis and treatment; Diagnosis (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing and others), Treatment (Therapeutics, surgeries and others) by End users (Hospitals & Clinics, Gynecology Centers, Research Institutes, and others) - Forecast to 2023


Market Synopsis of Global Women Healthcare market:


Market Scenario:


Women health is referred to the health problems that are specific to women anatomy. It relates to the unique issues which includes pregnancy, menopause, and conditions of the female organs. Women health also includes medical situations in which women face problems not directly related to their biology but due to gender-differentiated access to medical treatment. Women's health issues have attained higher international perceptibility in the recent decades. The targeted policies and government initiatives to decrease the burden of the women health diseases have enabled women to lead healthier lives, while some significant gender-based health disparities remain in many countries. With limited awareness and less income levels in many developing countries are making health improvements for women exceptionally difficult.


The market for women healthcare is projected to grow at a steady CAGR of 5.04% during the forecast period from 2017-2023.


Research Methodology

Research Methodology of Women Healthcare market


Source: WHO (World Health Organization), CDC (Centre for Disease Control and Prevention), Food and Drug Administration (FDA), NHS (National Health Services),Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Women Healthcare products manufacturers & suppliers

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities


Figure 1           Global Women Healthcare Market by Indications, 2016 (%)

Global Women Healthcare Market by Indications, 2016


Segments:


The Women Healthcare Market is segmented on the basis of indications, diagnosis and treatment and also on the basis of end users. Based on the indications, the market has been segmented as postmenopausal osteoporosis, infertility, reproductive health management, polycystic ovary syndrome, gynecologic cancer and others. Gynecologic cancer segment has been further divided into breast, ovarian or other types of cancer. On the basis of diagnosis the market has been segmented as bone densitometry, diagnostic imaging tests, biopsies, ovulation testing and others. Similarly, on the basis of treatment the market has been classified as therapeutics, surgeries and others. Lastly on the basis of end users the market has been further classified into hospitals & clinics, gynecology centers, research institutes, and others


 


Regional analysis


On the basis of region the market is segmented into North America, Europe, Asia-Pacific and Middle East and Africa. North America was commands the largest market share which is expected to reach USD 21,782.6 million by 2023 due to well-developed economy and initiatives taken to promote women healthcare in the region. On the other hand factors such as high cost of diagnosis and treatments are restricting the market growth in the Middle East & African region, while Asia-Pacific countries are expected to be the fastest growing region with a CAGR of 5.46% from 2017-2023.  


Market players of Global Women Healthcare Industry:


Market players of Canadian healthcare industries are Allergan plc. (Ireland), Amgen (California), Bayer A G (Germany), Becton Dickinson and Company (U.S.), Eli Lilly Company (U.S.), Merck & Co., Inc., (U.S.), Pfizer Inc., (U.S.), and Teva Pharmaceuticals (Israel).

The report for Global women Healthcare Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

2.1 INTRODUCTION

2.2 SCOPE OF STUDY

2.3 RESEARCH OBJECTIVE

2.4 ASSUMPTIONS & LIMITATIONS

2.4.1 ASSUMPTIONS

2.4.2 LIMITATIONS

2.5 MARKET STRUCTURE

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASING POOR HEALTH CONDITIONS IS MAJOR CAUSE FOR FEMALE-SPECIFIC HEALTH ISSUES

4.2.2 GROWING EMPHASIS ON PREVENTIVE CARE SERVICES

4.2.3 INITIATIVES TAKEN TO PROMOTE WOMEN HEALTHCARE

4.2.4 INCREASE IN R&D ACTIVITIES BY MAJOR PLAYERS FOR WOMEN HEALTH

4.3 RESTRAINTS

4.3.1 HIGH COST OF DIAGNOSIS

4.3.2 HIGH COST OF TREATMENT

4.4 OPPORTUNITIES

4.4.1 EARLY DIAGNOSIS OF THE WOMEN HEALTH DISEASES

4.4.2 RISING AWARENESS FOR WOMEN HEALTH IN EMERGING NATIONS

4.5 CHALLENGE

4.5.1 CHALLENGES TO ACCESSING CARE

5.1 PORTERS FIVE FORCES MODEL

5.1.1 BARGAINING POWER OF SUPPLIERS

5.1.2 BARGAINING POWER OF BUYERS

5.1.3 THREAT OF NEW ENTRANTS

5.1.4 THREAT OF SUBSTITUTES

5.1.5 INTENSITY OF RIVALRY

5.2 VALUE CHAIN ANALYSIS

5.2.1 RESEARCH & DEVELOPMENT (R&D)

5.2.2 OPERATIONS

5.2.3 COMMERCIAL OPERATIONS AND DISTRIBUTION & PHARMACIES

5.2.4 CONSUMERS

6.1 INTRODUCTION

6.2 POSTMENOPAUSAL OSTEOPOROSIS

6.3 INFERTILITY

6.4 REPRODUCTIVE HEALTH MANAGEMENT

6.5 POLYCYSTIC OVARY SYNDROME

6.6 GYNECOLOGIC CANCER

6.7 OTHER INDICATIONS

7.1 INTRODUCTION

7.2 DIAGNOSIS

7.3 TREATMENT

8.1 INTRODUCTION

8.2 HOSPITALS & CLINICS

8.3 GYNECOLOGY CENTERS

8.4 RESEARCH INSTITUTES

8.5 OTHER END USER

9.1 INTRODUCTION

9.2 NORTH AMERICA

9.2.1 THE U.S.

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 REPUBLIC OF KOREA

9.4.5 REST OF ASIA-PACIFIC

9.5 MIDDLE EAST & AFRICA

9.5.1 UAE

9.5.2 SAUDI ARABIA

9.5.3 EGYPT

9.5.4 REST OF MIDDLE EAST & AFRICA

11.1 ALLERGAN PLC.

11.1.1 OVERVIEW

11.1.2 PRODUCT OVERVIEW

11.1.3 FINANCIALS

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.2 AMGEN

11.2.1 COMPANY OVERVIEW

11.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.2.3 FINANCIAL OVERVIEW

11.2.4 KEY DEVELOPMENT

11.2.5 SWOT ANALYSIS

11.3 BAYER AG

11.3.1 OVERVIEW

11.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.3.3 FINANCIAL UPDATES

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.4 BECTON, DICKINSON AND COMPANY

11.4.1 OVERVIEW

11.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.4.3 FINANCIAL UPDATES

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.5 ELI LILLY COMPANY

11.5.1 COMPANY OVERVIEW

11.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.5.3 FINANCIAL OVERVIEW

11.5.4 KEY DEVELOPMENT

11.5.5 SWOT ANALYSIS

11.6 MERCK & CO., INC.

11.6.1 OVERVIEW

11.6.2 PRODUCT OVERVIEW

11.6.3 FINANCIALS

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.7 PFIZER INC.

11.7.1 OVERVIEW

11.7.2 PRODUCT OVERVIEW

11.7.3 FINANCIALS

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD

11.8.1 COMPANY OVERVIEW

11.8.2 PRODUCT OVERVIEW

11.8.3 FINANCIAL OVERVIEW

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

TABLE 1 GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION) 29
TABLE 2 POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY REGION, 2014-2023 (USD MILLION) 31
TABLE 3 INFERTILITY MARKET, BY REGION, 2014-2023 (USD MILLION) 32
TABLE 4 REPRODUCTIVE HEALTH MANAGEMENT MARKET, BY REGION, 2014-2023 (USD MILLION) 33
TABLE 5 POLYCYSTIC OVARY SYNDROME MARKET, BY REGION, 2014-2023 (USD MILLION) 34
TABLE 6 GYNECOLOGIC CANCER MARKET, BY REGION, 2014-2023 (USD MILLION) 35
TABLE 7 OTHER INDICATIONS MARKET, BY REGION, 2014-2023 (USD MILLION) 36
TABLE 8 GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 37
TABLE 9 DIAGNOSIS MARKET, BY REGION, 2014-2023 (USD MILLION) 39
TABLE 10 TREATMENT MARKET, BY REGION, 2014-2023 (USD MILLION) 40
TABLE 11 GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 41
TABLE 12 HOSPITALS & CLINICS MARKET, BY REGION, 2014-2023 (USD MILLION) 43
TABLE 13 GYNECOLOGY CENTERS MARKET, BY REGION, 2014-2023 (USD MILLION) 44
TABLE 14 RESEARCH INSTITUTES MARKET, BY REGION, 2014-2023 (USD MILLION) 45
TABLE 15 OTHER END USER MARKET, BY REGION, 2014-2023 (USD MILLION) 46
TABLE 16 GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2014-2023 (USD MILLION) 47
TABLE 17 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 49
TABLE 18 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION) 50
TABLE 19 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 51
TABLE 20 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 52
TABLE 21 U.S. WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 52
TABLE 22 U.S. WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 53
TABLE 23 U.S. WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 54
TABLE 24 CANADA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 54
TABLE 25 CANADA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 55
TABLE 26 CANADA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 56
TABLE 27 EUROPE LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 57
TABLE 28 EUROPE WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION) 58
TABLE 29 EUROPE WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 59
TABLE 30 EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 60
TABLE 31 GERMANY WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 60
TABLE 32 GERMANY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 61
TABLE 33 GERMANY WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 62
TABLE 34 FRANCE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 62
TABLE 35 FRANCE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 63
TABLE 36 FRANCE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 64
TABLE 37 UK WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 64
TABLE 38 UK WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 65
TABLE 39 UK WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 66
TABLE 40 ITALY WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 66
TABLE 41 ITALY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 67
TABLE 42 ITALY WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 68
TABLE 43 SPAIN WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 68
TABLE 44 SPAIN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 69
TABLE 45 SPAIN WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 70
TABLE 46 REST OF EUROPE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 70
TABLE 47 REST OF EUROPE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 71
TABLE 48 REST OF EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 72
TABLE 49 ASIA-PACIFIC LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 73
TABLE 50 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION) 74
TABLE 51 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 75
TABLE 52 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 76
TABLE 53 JAPAN WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 76
TABLE 54 JAPAN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 77
TABLE 55 JAPAN WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 78
TABLE 56 CHINA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 78
TABLE 57 CHINA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 79
TABLE 58 CHINA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 80
TABLE 59 INDIA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 80
TABLE 60 INDIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 81
TABLE 61 INDIA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 82
TABLE 62 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 83
TABLE 63 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 84
TABLE 64 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 85
TABLE 65 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 86
TABLE 66 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 87
TABLE 67 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 88
TABLE 68 MIDDLE EAST & AFRICA LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 89
TABLE 69 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION) 90
TABLE 70 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 91
TABLE 71 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 92
TABLE 72 UAE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 93
TABLE 73 UAE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 94
TABLE 74 UAE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 95
TABLE 75 SAUDI ARABIA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 95
TABLE 76 SAUDI ARABIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 96
TABLE 77 SAUDI ARABIA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 97
TABLE 78 EGYPT WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 97
TABLE 79 EGYPT WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 98
TABLE 80 EGYPT WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 99
TABLE 81 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION) 100
TABLE 82 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 101
TABLE 83 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 102
TABLE 84 AMGEN: KEY DEVELOPMENT 109
TABLE 85 ELI LILLY COMPANY : KEY DEVELOPMENT 119
TABLE 86 PFIZER: PRODUCT OVERVIEW 124
TABLE 87 PFIZER: KEY DEVELOPMENTS 126
TABLE 88 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS 130

FIGURE 1 GLOBAL WOMEN HEALTHCARE MARKET: MARKET STRUCTURE 17
FIGURE 2 RESEARCH PROCESS 18
FIGURE 3 GLOBAL WOMEN HEALTHCARE MARKET: PORTERS FIVE FORCES MODEL 25
FIGURE 4 GLOBAL WOMEN HEALTHCARE MARKET: VALUE CHAIN ANALYSIS 27
FIGURE 5 GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2016 & 2023 (USD MILLION) 30
FIGURE 6 GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2016 & 2023 (USD MILLION) 38
FIGURE 7 GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2016 & 2023 (USD MILLION) 42
FIGURE 8 GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2016 & 2023 (USD MILLION) 48
FIGURE 9 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%) 49
FIGURE 10 EUROPE WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%) 58
FIGURE 11 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%) 74
FIGURE 12 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%) 89
FIGURE 13 GLOBAL WOMEN HEALTHCARE MARKET: COMPETITIVE LANDSCAPE 103
FIGURE 14 ALLERGAN PLC: FINANCIAL REVENUE 105
FIGURE 15 ALLERGAN PLC: SEGMENTAL REVENUE 105
FIGURE 16 AMGEN: RECENT FINANCIAL 108
FIGURE 17 AMGEN: GEOGRAPHIC REVENUE MIX 108
FIGURE 18 AMGEN: SWOT ANALYSIS 109
FIGURE 19 BAYER AG: FINANCIAL REVENUE 110
FIGURE 20 BAYER AG: SEGMENTAL REVENUE 111
FIGURE 21 BAYER AG: GEOGRAPHICAL REVENUE 111
FIGURE 22 BAYER AG: SWOT ANALYSIS 112
FIGURE 23 BECTON, DICKINSON AND COMPANY: FINANCIAL REVENUE 113
FIGURE 24 BECTON, DICKINSON AND COMPANY: SEGMENTAL REVENUE 114
FIGURE 25 BECTON, DICKINSON AND COMPANY: GEOGRAPHICAL REVENUE 114
FIGURE 26 BECTON, DICKINSON & COMPANY: SWOT ANALYSIS 116
FIGURE 27 ELI LILLY COMPANY : RECENT FINANCIAL 118
FIGURE 28 ELI LILLY COMPANY : BUSINESS REVENUE MIX (2015) 118
FIGURE 29 ELI LILLY COMPANY : GEOGRAPHIC REVENUE MIX 119
FIGURE 30 ELI LILLY COMPANY : SWOT ANALYSIS 120
FIGURE 31 MERCK & CO., INC.: FINANCIAL REVENUE 121
FIGURE 32 MERCK & CO., INC.: SEGMENTAL REVENUE 122
FIGURE 33 MERCK & CO., INC.: GEOGRAPHIC REVENUE 122
FIGURE 34 PFIZER: FINANCIAL REVENUE 125
FIGURE 35 PFIZER: SEGMENTAL REVENUE 125
FIGURE 36 PFIZER: GEOGRAPHIC REVENUE 126
FIGURE 37 PFIZER: SWOT ANALYSIS 127
FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT FINANCIALS 128
FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL MIX, 2016 (%) 129
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS, 2016 (%) 129
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 131